<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360071</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00107909</org_study_id>
    <nct_id>NCT03360071</nct_id>
  </id_info>
  <brief_title>A Novel Biologic Therapy for Perennial Allergic Rhinitis</brief_title>
  <official_title>A Double-blind, Prospective, Parallel Group Evaluation of a Novel Biologic Therapy for Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept
      study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as
      a sub-cutaneously administered immunotherapy for the management of allergic rhinitis
      (perennial and seasonal).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept
      study which will evaluate the effect of a proprietory mixed preparation of FDA approved
      allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of
      allergic rhinitis (perennial and seasonal). Participating study subjects will be required to
      manifest the signs and symptoms of allergic rhinitis and test positive to at least six
      allergens using a multi aeroallergen screen at the time of study recruitment . All subjects
      will undergo standard allergen skin prick testing using six Multi-TestÂ® PC skin prick test
      devices (Lincoln Diagnostics, Decator, IL) or comparable skin testing technique for a total
      of 48 Skin Prick Test (SPT). Approximately 36 total subjects will be enrolled.

      Following a successful screening study visit and two week medication washout period, a 8 week
      treatment period will be initiated with bi-weekly study visits being undertaken, through to
      the end of immunotherapy, for assessment of therapeutic response and safety evaluations.
      Efficacy evaluation will be monitored using validated instruments that assess study subject
      clinical response, physician global assessment, and medication use. A safety assessment will
      be undertaken one month following completion of treatment.

      At the screening visit (Screening Visit) a potential study subject will be required to
      fulfill the requirements of the study inclusion and exclusion criteria, will have a clinical
      evaluation including medical history and physical examination, blood draw and performance of
      skin testing. The study subject will then abstain from using intranasal steroids and
      antihistamines for two weeks and then return to the clinic for administration of
      sub-cutaneous PMA and post-treatment in-clinic safety evaluation. The latter evaluation
      period will comprise approximately 60 minutes to assess the study subject's response to PMA
      immunotherapy. Follow up clinic study visits will continue bi-weekly through 8 weeks and at
      each of these visits the study subject will receive increasing doses of PMA immunotherapy and
      will be evaluated for safety. Twice weekly clinical evaluation will also be performed.
      Following the final administration of PMA immunotherapy, a one month follow-up safety and
      clinical efficacy evaluation will be conducted by telephone or in the clinic. The duration of
      the study will be approximately 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2016</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Combined Score (DCS)</measure>
    <time_frame>Change from baseline at 10 weeks</time_frame>
    <description>Change in baseline. TNSS (Total Nasal Symptoms Score) + medication rescue score. TNSS is a scale of 0-12 with 12 being severe. Medication score is also 0-12 with 12 being highest use of medications. Thus DCS ranges from 0-24 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini RQLQ</measure>
    <time_frame>Change from baseline at 10 weeks</time_frame>
    <description>mini-RQLQ (mini-Rhinoconjunctivitis Quality of Life Questionnaire) is to measure a the level of severity of a set of symptoms of functional impairments due to rhinoconjunctivitis from baseline. 14 questions each range 0-6 (6 is most severe). Total range 0-84 (higher value is more severe symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>Duration of intervention plus followup (12 weeks)</time_frame>
    <description>Use of epinephrine during intervention for a total of 8 weeks through followup and study completion (4 more weeks). Thus total number of times epinephrine is required per patient during entire 12 week period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>continuous review of safety up to 14 week</time_frame>
    <description>Safety and adverse events (AES) will be followed. We will measure and report systemic reactions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergen Immunotherapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allergen Immunotherapy Extract</intervention_name>
    <description>Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
    <arm_group_label>Allergen Immunotherapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allergen Immunotherapy Control</intervention_name>
    <description>Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator, the subject is capable of understanding and
             complying with protocol requirements.

          -  The subject signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures.

          -  The subject is a male or a non-pregnant, non-lactating female between the ages of 18
             and 65.

          -  The subject is actively manifesting symptoms and signs of moderate to severe Perennial
             Allergic Rhinitis (PAR) with or without Seasonal Allergic Rhinitis (SAR) component
             defined as score of at least 28 on the Rhinoconjunctivitis Quality of Life
             Questionnaire (RQLQ) and 6 on the Total Nasal Symptom Score (TNSS) scale. Scores will
             be determined on the first and second visit (after the 14 day medication washout
             period). Both scores exceeding their threshold on either day will qualify.

          -  Skin test strongly positive (wheal at least 5mm diameter and 2mm greater than negative
             control) to at least 6 of 48 allergy skin prick tests including at least one species
             of dust mite.

        Exclusion Criteria:

          -  The subject has received any investigational compound within 30 days prior to
             screening.

          -  The subject has received allergen immunotherapy or Sublingual immunotherapy (SLIT) in
             a previous clinical study or as a therapeutic agent within the past two years.

          -  The subject has a history or clinical manifestations of significant medical conditions
             (cardiovascular, hepatic, infectious or renal disease, etc.) which in the opinion of
             the investigator renders them unacceptable study subjects.

          -  The subject has a history of drug abuse (defined as any chronic illicit drug use) or a
             history of alcohol abuse within 5 years prior to the screening visit.

          -  The subject is required to take excluded medications listed in Section 6.3.

          -  If female, the subject is pregnant or lactating or intending to become pregnant
             before, during, or within 1 month after participating in this study; or intending to
             donate ova during such time period.

          -  Subjects found to have on physical exam significant nasal polyps, septal deviation or
             infectious sinusitis.

          -  The subject has a history of allergic rhinitis but is not currently manifesting active
             signs and symptoms of the disorder.

          -  Subject has a history of cancer, other than squamous cell or basal cell carcinoma of
             the skin that has not been in full remission for at least 5 years prior to Screening.
             (A history of treated Cervical Intraepithelial Neoplasia (CIN) I, II, or CIN III is
             allowed.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <results_first_submitted>July 1, 2019</results_first_submitted>
  <results_first_submitted_qc>August 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03360071/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allergen Immunotherapy Group</title>
          <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allergen Immunotherapy Group</title>
          <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="1"/>
                    <measurement group_id="B2" value="39" spread="1"/>
                    <measurement group_id="B3" value="36.8" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daily Combined Score (DCS)</title>
        <description>Change in baseline. TNSS (Total Nasal Symptoms Score) + medication rescue score. TNSS is a scale of 0-12 with 12 being severe. Medication score is also 0-12 with 12 being highest use of medications. Thus DCS ranges from 0-24 (severe).</description>
        <time_frame>Change from baseline at 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergen Immunotherapy Group</title>
            <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Combined Score (DCS)</title>
          <description>Change in baseline. TNSS (Total Nasal Symptoms Score) + medication rescue score. TNSS is a scale of 0-12 with 12 being severe. Medication score is also 0-12 with 12 being highest use of medications. Thus DCS ranges from 0-24 (severe).</description>
          <units>DCS (daily combined score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.41" spread="4.5"/>
                    <measurement group_id="O2" value="-1.61" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mini RQLQ</title>
        <description>mini-RQLQ (mini-Rhinoconjunctivitis Quality of Life Questionnaire) is to measure a the level of severity of a set of symptoms of functional impairments due to rhinoconjunctivitis from baseline. 14 questions each range 0-6 (6 is most severe). Total range 0-84 (higher value is more severe symptoms).</description>
        <time_frame>Change from baseline at 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergen Immunotherapy Group</title>
            <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mini RQLQ</title>
          <description>mini-RQLQ (mini-Rhinoconjunctivitis Quality of Life Questionnaire) is to measure a the level of severity of a set of symptoms of functional impairments due to rhinoconjunctivitis from baseline. 14 questions each range 0-6 (6 is most severe). Total range 0-84 (higher value is more severe symptoms).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.9" spread="28.4"/>
                    <measurement group_id="O2" value="-17.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use</title>
        <description>Use of epinephrine during intervention for a total of 8 weeks through followup and study completion (4 more weeks). Thus total number of times epinephrine is required per patient during entire 12 week period.</description>
        <time_frame>Duration of intervention plus followup (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergen Immunotherapy Group</title>
            <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use</title>
          <description>Use of epinephrine during intervention for a total of 8 weeks through followup and study completion (4 more weeks). Thus total number of times epinephrine is required per patient during entire 12 week period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment</title>
        <description>Safety and adverse events (AES) will be followed. We will measure and report systemic reactions.</description>
        <time_frame>continuous review of safety up to 14 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergen Immunotherapy Group</title>
            <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment</title>
          <description>Safety and adverse events (AES) will be followed. We will measure and report systemic reactions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of therapy until one month after therapy was completed (12 weeks total).</time_frame>
      <desc>We look at all adverse events but particularly systemic reaction rates including anaphylaxis and use of epinephrine (12 weeks total)</desc>
      <group_list>
        <group group_id="E1">
          <title>Allergen Immunotherapy Group</title>
          <description>Allergen Immunotherapy Extract: Allergen Immunotherapy treatment mixture to be delivered subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Allergen Immunotherapy Control: Allergen Immunotherapy Control Solution to be delivered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>systemic reaction</sub_title>
                <description>mild systemic reaction defined by local inflammation and/or flushing or hives.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication must be approved by sponsor within first 10 years after completion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jody Tversky, MD</name_or_title>
      <organization>John Hopkins University School of Medicine</organization>
      <phone>410-550-2300</phone>
      <email>hoddin1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

